Mace  Rothenberg net worth and biography

Mace Rothenberg Biography and Net Worth

Director of Tango Therapeutics

Mace Rothenberg, MD, most recently served as as chief medical officer of Pfizer. He is a transformative leader who has built and led highly successful teams over a 30-year career spanning academia and the biopharmaceutical industry.

At Pfizer, Mace’s organization developed and obtained regulatory approval for an industry-leading 11 new cancer medicines. He is the recipient of the first Craig Saxton Lifetime Achievement Award from Pfizer for his success in cancer drug development.

Prior to joining Pfizer, he spent 25 years in academia, with significant accomplishments including serving as Principal Investigator on clinical trials, tripling the size of the clinical programs, and mentoring dozens of early career clinical and translational researchers. Mace has served on the faculties of the University of Texas Health Science Center–San Antonio and Vanderbilt University Medical Center and was named the 2020 Mitchell Blutt Visiting Professor for Entrepreneurism and Medicine at the Perelman School of Medicine of the University of Pennsylvania. He was also the recipient of the Lane W. Adams Quality of Life Award from the American Cancer Society and the Statesman Award from the American Society of Clinical Oncology for his years of service to cancer patients.

Mace is a member of the American College of Physicians and the American Society of Clinical Oncology and is board-certified in Internal Medicine and Medical Oncology. Mace is a graduate of the New York University School of Medicine, completed his residency in Internal Medicine at Vanderbilt University and his fellowship in Medical Oncology at the National Cancer Institute.

What is Mace Rothenberg's net worth?

The estimated net worth of Mace Rothenberg is at least $309.38 thousand as of November 18th, 2024. Rothenberg owns 31,250 shares of Tango Therapeutics stock worth more than $309,375 as of December 4th. This net worth evaluation does not reflect any other assets that Rothenberg may own. Learn More about Mace Rothenberg's net worth.

How do I contact Mace Rothenberg?

The corporate mailing address for Rothenberg and other Tango Therapeutics executives is 12860 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. Tango Therapeutics can also be reached via phone at 857-320-4900 and via email at [email protected]. Learn More on Mace Rothenberg's contact information.

Has Mace Rothenberg been buying or selling shares of Tango Therapeutics?

Mace Rothenberg has not been actively trading shares of Tango Therapeutics within the last three months. Most recently, on Monday, November 18th, Mace Rothenberg bought 10,000 shares of Tango Therapeutics stock. The stock was acquired at an average cost of $3.78 per share, with a total value of $37,800.00. Following the completion of the transaction, the director now directly owns 31,250 shares of the company's stock, valued at $118,125. Learn More on Mace Rothenberg's trading history.

Who are Tango Therapeutics' active insiders?

Tango Therapeutics' insider roster includes Douglas Barry (Chief Legal Officer), Daniella Beckman (CFO), Adam Crystal (President, Research & Development), Mace Rothenberg (Director), and Barbara Weber (CEO). Learn More on Tango Therapeutics' active insiders.

Are insiders buying or selling shares of Tango Therapeutics?

During the last year, insiders at the sold shares 11 times. They sold a total of 3,496,769 shares worth more than $26,422,881.47. The most recent insider tranaction occured on October, 23rd when Major Shareholder Rock Ventures Iv L.P. Third sold 477,401 shares worth more than $4,845,620.15. Insiders at Tango Therapeutics own 7.5% of the company. Learn More about insider trades at Tango Therapeutics.

Information on this page was last updated on 10/23/2025.

Mace Rothenberg Insider Trading History at Tango Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/18/2024Buy10,000$3.78$37,800.0031,250View SEC Filing Icon  
11/14/2024Buy10,000$3.62$36,200.0021,250View SEC Filing Icon  
See Full Table

Mace Rothenberg Buying and Selling Activity at Tango Therapeutics

This chart shows Mace Rothenberg's buying and selling at Tango Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Tango Therapeutics Company Overview

Tango Therapeutics logo
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $9.90
Low: $9.46
High: $10.22

50 Day Range

MA: $8.54
Low: $6.91
High: $10.92

2 Week Range

Now: $9.90
Low: $1.03
High: $11.20

Volume

2,780,322 shs

Average Volume

2,935,051 shs

Market Capitalization

$1.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.72